Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Back

ESC Professional Premium Access

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Session: Insights from recent HFpEF trials 1

Topic: Pharmacotherapy

Speaker: Doctor M. Pabon (Boston, US)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Maria Pabon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

1 presentation

0 follower

5 more presentations in this session

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Speaker: Doctor S. Chatur (Boston, US)

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Speaker: Doctor X. Wang (Boston, US)

Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF

Speaker: Professor C. Saldarriaga (Medellin, CO)

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

Speaker: Professor B. Pitt (Ann Arbor, US)

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

Speaker: Doctor M. Sumin (Mainz, DE)

Access the full session

Insights from recent HFpEF trials 1

Speakers: Doctor M. Pabon, Doctor S. Chatur, Doctor X. Wang, Professor C. Saldarriaga, Professor B. Pitt...

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources